Nedosiran

Rivfloza (Nedosiran)

Drug Overview

Nedosiran represents a groundbreaking pharmacological advancement within the Nephrology specialty. Categorized under the Rivfloza (Nedosiran) drug class, representing a highly advanced subclass of small interfering RNA (siRNA) therapeutics, this medication offers a transformative approach to treating severe genetic kidney diseases. As an international health brand committed to cutting-edge precision medicine, we recognize this Biologic agent as a sophisticated Smart Drug. It does not merely manage the downstream symptoms of kidney stones; instead, it intercepts the disease at the genetic level within the liver, halting the metabolic cascade that ultimately destroys renal tissue.

• Generic Name: Nedosiran
• US Brand Names: Rivfloza™
• Drug Category: Nephrology (and Genomic Medicine)
• Drug Class: Rivfloza (Nedosiran) / RNA Interference (RNAi) Therapeutics
• Route of Administration: Subcutaneous injection
• FDA Approval Status: Fully FDA-approved for the treatment of Primary Hyperoxaluria Type 1 (PH1) in adult and pediatric patients (2 years of age and older) with relatively preserved kidney function.
  
  Discover Rivfloza (Nedosiran), a new RNAi therapy that prevents oxalate accumulation by targeting the LDH enzyme. Read our comprehensive medical overview.

What Is It and How Does It Work? (Mechanism of Action)

Primary Hyperoxaluria Type 1 (PH1) is a rare, life-threatening autosomal recessive disorder. Due to a mutation in the AGXT gene, the liver lacks a functional enzyme required to process glyoxylate. Consequently, glyoxylate is shunted into an alternative metabolic pathway where it is converted into oxalate. Because humans cannot metabolize oxalate, it must be excreted by the kidneys. In PH1, the massive overproduction of oxalate causes it to bind with calcium, forming sharp, insoluble calcium oxalate crystals that accumulate in the renal tubules, leading to severe nephrocalcinosis, kidney failure, and eventually systemic oxalosis.

Nedosiran functions as a highly precise Targeted Therapy utilizing RNA interference (RNAi) technology. At the molecular level, nedosiran is a synthetic, double-stranded siRNA molecule covalently linked to an N-acetyl-D-galactosamine (GalNAc) ligand. This GalNAc sugar moiety acts as a highly specific “homing beacon” that binds exclusively to asialoglycoprotein receptors (ASGPR) located abundantly on the surface of hepatocytes (liver cells).

Upon binding, the nedosiran-receptor complex is rapidly internalized into the hepatocyte via endocytosis. Inside the cell, the double-stranded RNA unwinds, and the active antisense strand is incorporated into the RNA-induced silencing complex (RISC). The RISC-nedosiran complex then specifically targets, binds to, and degrades the messenger RNA (mRNA) that encodes the hepatic enzyme Lactate Dehydrogenase A (LDHA). By silencing LDHA mRNA, the liver is prevented from synthesizing the LDH enzyme. Because LDH is responsible for catalyzing the final biochemical step that converts glyoxylate into toxic oxalate, its inhibition fundamentally cuts off oxalate production at its source.

FDA-Approved Clinical Indications

Primary Indication

• New RNAi therapy that prevents oxalate accumulation by targeting the LDH enzyme: Specifically indicated to lower urinary oxalate levels in children 2 years of age and older, and adults with Primary Hyperoxaluria Type 1 (PH1) who have relatively preserved kidney function (e.g., an estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m²).

Other Approved Uses

• Currently, nedosiran is exclusively FDA-approved for Primary Hyperoxaluria Type 1 (PH1).
• Note: While the molecular mechanism of targeting LDH theoretically applies to other subtypes of Primary Hyperoxaluria (such as PH2 and PH3), the FDA has currently restricted approval strictly to PH1 based on the populations evaluated in the pivotal clinical trials.

Dosage and Administration Protocols

Nedosiran dosing is administered once monthly via subcutaneous injection. The dosage is strictly determined by the patient’s actual body weight and age.

Dose Adjustments and Specific Patient Populations:

• Renal Insufficiency: No dosage adjustment is required for patients with mild to moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m²). Nedosiran has not been studied, and is not currently recommended, for patients with severe renal impairment or End-Stage Renal Disease (eGFR < 30 mL/min/1.73 m²).
• Hepatic Insufficiency: No dosage adjustment is required for patients with mild hepatic impairment. It has not been evaluated in patients with moderate or severe hepatic impairment.
• Missed Doses: If a planned dose is missed by fewer than 7 days, administer it as soon as possible. If missed by more than 7 days, administer it as soon as possible and resume the standard monthly schedule from that date.

Clinical Efficacy and Research Results

The clinical efficacy of nedosiran was established primarily through the landmark PHYOX2 randomized, double-blind, placebo-controlled phase 2/3 clinical trial (data published 2023–2025).

In patients with PH1 and preserved kidney function, the administration of nedosiran yielded profound biomarker improvements. The primary efficacy endpoint—measured as the area under the curve (AUC) of the percent change from baseline in 24-hour urinary oxalate (Uox) excretion from day 90 to day 180—demonstrated a highly statistically significant reduction in the nedosiran cohort compared to placebo.

Clinical data registries indicate that treated patients consistently achieve a 40% to 60% reduction in urinary oxalate excretion relative to their baselines. A significant majority of patients treated with nedosiran reached normal or near-normal urinary oxalate levels, effectively halting the supersaturation of calcium oxalate in the renal filtrate. By arresting the continuous formation of kidney stones and preventing nephrocalcinosis, this intervention dramatically slows disease progression, preserving long-term renal function and delaying or eliminating the eventual need for liver-kidney transplantation.

Safety Profile and Side Effects

Important Safety Warning: Nedosiran does not carry an FDA Black Box Warning. Due to its advanced GalNAc-conjugated delivery system, this Immunotherapy is restricted almost entirely to the liver, resulting in an exceptionally favorable systemic safety profile compared to traditional systemic agents.

Common Side Effects (>10%)

• Injection Site Reactions (ISRs): The most frequently documented adverse event. Symptoms include localized erythema (redness), pain, bruising, and mild swelling at the subcutaneous injection site. These are typically mild and self-limiting.

Serious Adverse Events

• Hypersensitivity: As with all biologic and peptide-based therapies, there is a rare potential for hypersensitivity or allergic reactions.
• Lack of Efficacy in Severe Renal Failure: While not a direct toxic effect, the drug has not proven efficacy in patients whose eGFR has already fallen below 30 mL/min/1.73 m², and its use is contraindicated in that subpopulation to prevent unmonitored accumulation.

Management Strategies

• ISR Management: Rotate injection sites strictly among the abdomen (staying at least 2 inches away from the navel) and the upper thighs. Do not inject into scarred, inflamed, or bruised skin. Applying a cold compress after the injection can alleviate local discomfort.
• Regular Monitoring: Because the drug acts on hepatic enzymes, periodic monitoring of standard liver function tests (AST, ALT, Bilirubin) is advisable, alongside routine renal panels to track the drug’s ongoing efficacy.

Connection to Stem Cell and Regenerative Medicine

Historically, the only definitive cure for Primary Hyperoxaluria was a highly morbid combined liver and kidney transplant. Nedosiran acts as a pharmacological proxy for a liver transplant, utilizing RNA interference to genetically silence the defective metabolic pathway.

In the context of Regenerative Medicine, preventing calcium oxalate crystal deposition is paramount to preserving the delicate architectural scaffolding of the renal interstitium and tubules. When chronic crystallization is allowed to persist, it triggers irreversible interstitial fibrosis, rendering the kidney hostile to any cellular repair mechanisms. By utilizing this Targeted Therapy to arrest nephrocalcinosis early in the disease course, nedosiran preserves the native, healthy renal microenvironment. This tissue preservation ensures that the patient remains a viable candidate for future, advanced regenerative nephrology interventions—such as endogenous stem cell activation or bioengineered tubular cell grafts—aimed at repairing pre-existing focal tubular damage without the threat of recurrent crystal destruction.

Patient Management and Practical Recommendations

Pre-Treatment Tests

• Genetic Confirmation: Documented genetic testing confirming an AGXT gene mutation (to verify PH1) or liver biopsy demonstrating absent AGT enzyme activity is required before initiation.
• Biomarker Baseline: Baseline 24-hour urinary oxalate excretion levels (or spot urinary oxalate:creatinine ratio) to quantify disease severity.
• Renal Function: A Comprehensive Metabolic Panel (CMP) to establish baseline eGFR to ensure the patient meets the ≥ 30 mL/min/1.73 m² threshold.

Precautions During Treatment

• Hyperhydration Must Continue: Nedosiran stops new oxalate from being produced, but it does not dissolve existing kidney stones. Patients must maintain aggressive, lifelong high fluid intake (typically > 3 liters/1.73 m² per day) to continuously flush the kidneys and prevent the precipitation of any residual oxalate.
• Pyridoxine (Vitamin B6) Therapy: Many PH1 patients have a genotype that is partially responsive to Vitamin B6. Unless the patient is a documented non-responder, current clinical protocols recommend continuing pyridoxine therapy in combination with nedosiran.

Do’s and Don’ts

• DO continue drinking massive amounts of water every single day, exactly as prescribed by your nephrologist, to protect your kidneys from any remaining oxalate.
• DO attend all scheduled monthly appointments for your subcutaneous injections; skipping a dose allows the liver to immediately resume toxic oxalate production.
• DO rotate the sites of your injections (between your abdomen and thighs) each month to prevent your skin from becoming tough or irritated.
• DON’T stop taking your other prescribed kidney stone medications, such as Vitamin B6 or potassium citrate, unless your nephrologist explicitly tells you to do so.
• DON’T ignore signs of a kidney stone passing—such as severe back or flank pain, fever, or blood in your urine. Older stones that formed before you started the medication can still dislodge and require medical attention.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment plan. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.